Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
Nuvectis Pharma, a clinical-stage biopharmaceutical company, reported its Q2 2026 financial results and significant business achievements, including the in-licensing of two new drug candidates, ciprocopan (NXP100) and NXP200. The company announced that ciprocopan received marketing approval in China for PNH treatment and successfully raised …